ArticlePCN reports : psychiatry and clinical neurosciences2026
Serial FDG-PET in probable seronegative autoimmune encephalitis presenting as severe behavioral regression in a child with autism.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune encephalitis in children may present with predominant psychiatric and behavioral symptoms, creating diagnostic challenges, particularly in patients with pre-existing autism spectrum disorder. Seronegative forms are especially difficult to recognize because neuronal autoantibodies are not detected, and diagnostic overshadowing may delay consideration of immune-mediated etiologies. Case Presentation: We report the case of an 11-year-old boy of Turkish background living in France, with autism and normal intelligence, who developed severe subacute behavioral and cognitive regression. Symptoms included explosive aggression, self-injurious behavior, obsessive-compulsive-like behavioral loops, psychotic-like features, agitated catatonic deterioration from baseline, loss of adaptive skills, and marked functional decline. The condition was resistant to intensive psychiatric care and multiple psychotropic treatments. Etiological assessment revealed focal epilepsy, cerebrospinal fluid abnormalities, and abnormal brain fluorodeoxyglucose positron emission tomography (FDG-PET) findings, while extensive work-up excluded infectious, metabolic, genetic, systemic autoimmune, and oncological causes. Neuronal autoantibodies were negative in serum and cerebrospinal fluid. A cautious diagnosis of probable seronegative autoimmune encephalitis was retained based on the clinical course, focal epilepsy, serial FDG-PET abnormalities, follow-up cerebrospinal fluid findings, exclusion of alternative etiologies, and expert consensus. Intravenous immunoglobulin therapy was associated with progressive but partial clinical improvement, and rituximab was introduced after a response plateau. Conclusion: This case highlights the risk of diagnostic overshadowing in children with autism presenting with severe, treatment-resistant behavioral or catatonic regression. Immune-mediated etiologies should be considered even in the absence of detectable autoantibodies. Serial FDG-PET may support diagnostic reasoning and follow-up, while remaining nonspecific and insufficient as diagnostic proof in isolation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.